Memory Studies

BMS-986446

This clinical trial’s goal is to determine the impact BMS-986446 on cognitive and functional decline in participants with early Alzheimer’s disease. BMS-986446 is an anti-MTBR Tau Monoclonal antibody.

Eligibility: Individuals who have mild cognitive impairment (MCI) or early Alzheimer’s disease.

Status: RECRUITING

ACU193

This clinical trial examines ACU193 for how it affects individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI). This new antibody binds to the Aβ-derived diffusible ligands (ADDLs), which are believed to increase memory problems and brain cell death.

Eligibility: Individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI).

Status: RECRUITING

JNJ-63733657

Focusing on early Alzheimer’s, this study tests the anti-tau antibody, JNJ-63733657, against a placebo, assessing its potential to slow disease progression. This study is for people who do not have an Alzheimer’s disease diagnosis or symptoms, rather they are at a risk for the condition.

Eligibility: Individuals that are healthy with risk of Alzheimer’s disease.

Status: RECRUITING

Masupirdine

This clinical trial is testing Masupirdine‘s effectiveness on calming agitation that often affects those with Alzheimer’s disease. This oral medication is a selective antagonist of the 5-HT6 serotonin receptor.

Eligibility: Individuals with Alzheimer’s disease with untreated agitation.

Status: RECRUITING

HOPE

This study assesses the impact the COGNITO device has on slowing Alzheimer’s disease’s progression. We measure the effects the device’s visual and audio stimulation has on the participant’s daily activities and cognitive functions.

Eligibility: Individuals with mild to moderate Alzheimer’s disease.

Status: RECRUITING

Clarity AD

Lecanemab antibody targets amyloid-beta plaques in the brain to potentially slow the progression of Alzheimer’s disease. This study examines its impact on cognitive function over 18 months, with an extension phase to monitor long-term safety and effects.

Status: ACTIVE, NOT RECRUITING

FDA Approved

Simufilam

Following initial Phase 3 clinical trials, this study extends our investigation into Simufilam‘s long-term efficacy for patients with Alzheimer’s disease. Participants continue to receive Simufilam to monitor ongoing effects on improving cognitive functions and slowing down Alzheimer’s disease progression.

Status: ACTIVE, NOT RECRUITING

Bepranemab

This study assesses Bepranemab, an anti-tau antibody treatment aiming to modify the course of Alzheimer’s by targeting tau pathology. It explores the drug’s impact on improving cognitive outcomes in individuals with early Alzheimer’s disease and Mild Cognitive Impairment (MCI).

Status: ACTIVE, NOT RECRUITING

AACI

This critical trial explores Donanemab‘s potential in preventing the progression of early Alzheimer’s disease by targeting amyloid plaques in the brain. This N3pG antibody aims to halt or slow cognitive decline. This study holds promise for early intervention in Alzheimer’s disease’s progression.

Status: ACTIVE, NOT RECRUITING

FDA Approved

Fosgonimeton

This clinical trial examines the long-term tolerability of Fosgonimeton (ATH-1017) over an additional 4-year period in subjects with mild to moderate Alzheimer’s disease.  This trial is an extension of Study ATH-1017-AD-0201 and Study ATH-1017-AD-0202.

Status: ACTIVE, NOT RECRUITING